image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Filing date Description Form View

Registration of certain classes of securities 12(b) of the Securities Exchange Act

8-A12B View HTML

CORRESP

CORRESP View HTML

Registration statement for face-amount certificate companies

S-1 View HTML

Amendment to a previously filed DRS

DRS/A View HTML

UPLOAD

UPLOAD View HTML

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

DRS View HTML
D View HTML
D View HTML
D View HTML
D/A View HTML

Data provided by Kaleidoscope.